Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANDELA: High-Dose Aflibercept in nAMD
NCT04126317Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of aflibercept in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of Participants With at Least One Treatment-Emergent Adverse Event at Week 44, Number of Participants With at Least One Serious Treatment-Emergent Adverse Event at Week 44 and 1 more. Started Nov 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04126317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126317.